Cheap Website Traffic

Wockhardt, Serum Institute of India tie up to make vaccines in UK


Mumbai-based Wockhardt and Serum Life Sciences, a subsidiary of Serum Institute of India (SII), have entered into a partnership to make 150 million doses of SII vaccines in Wockhardt’s UK plant.

“This is a profit-sharing arrangement whereby we are setting up a new facility at Wrexham in North Wales. The investment on the facility is a joint venture between the two partners. It will be able to make 150 million doses of any SII vaccine for which they deliver the drug substance to us,” Habil Khorakiwala, chairman, Wockhardt, told Business Standard.

This will be a fill-and-finish facility for vaccines.

According to sources, it will take at least one and a half to two years before the new facility is ready.

Serum Lifesciences UK, a subsidiary of SII, and a Wockhardt subsidiary have entered into a profit-sharing arrangement for this new facility.

Natasha Poonawalla, chairperson, Serum Life Sciences, added, “We are delighted to have formed a strategic partnership between Wockhardt and Serum Life Sciences. The collaboration will be instrumental in building long-term capacity in the UK. With this, we seek to further bolster supply resilience and support the global rollout of vaccines.”

SII has supplied the AstraZeneca-Oxford vaccine to the UK already, and having a fill-and-finish facility in the UK would help the firm to have closer access to the UK and EU markets.

Serum Life Sciences looks after SII’s global expansion plans. Wockhardt has been looking at vaccine manufacturing partnerships.

Apart from India, Wockhardt owns plants in the UK and Ireland. The UK plant makes the AstraZeneca vaccine for the UK government.

Murtaza Khorakiwala, managing director (MD) and global chief executive officer (global CEO) of Wockhardt, said, “This deal signifies the role that we will now play in the global supply of multiple vaccines, protecting citizens against infectious diseases.”

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor


Source link

Cheap Website Traffic